Trial Profile

A crossover, randomized pharmacokinetic study of comparison of Epidiolex with two solid formulations in volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary) ; Cannabidiol; Cannabidiol
Indications Blepharospasm; Dravet syndrome; Epilepsy; Heroin-related disorders; Infantile spasms; Lennox-Gastaut syndrome; Opioid-related disorders; Parkinson's disease; Pervasive child development disorders; Rett syndrome; Sturge-Weber syndrome; Tuberous sclerosis
Focus Pharmacokinetics

Most Recent Events

05 Aug 2024 New trial record
30 Jul 2024 According to a 180 Life Sciences media release, trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital.
30 Jul 2024 According to a 180 Life Sciences media release, trial results are planned to be submitted for scientific publication at a later date.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com